Li Auto delivers 40,856 vehicles in May, up 16.7%
Li Auto (LI) announced that it delivered 40,856 vehicles in May 2025, representing a year-over-year increase of 16.7%. As of May 31, 2025, Li Auto's cumulative deliveries reached 1,301,531. Li Auto has completed a comprehensive upgrade of its entire model lineup to new versions over the past month. The deliveries of Li MEGA Home began in late May, and its production ramp up is accelerating as orders significantly exceeded expectations. The new Li L series demonstrates substantially enhanced product strengths, with each upgrade tailored to genuine user needs and optimized for high-frequency usage scenarios. Li L9 features the dual-chamber air suspension and dual-valve CDC flagship suspension system, delivering an exceptional balance of spacious interior comfort and stable handling. Meanwhile, both Li L8 and Li L7 feature dual-chamber Magic Carpet air suspension as standard, significantly boosting their sporting performance and setting them apart in the RMB300,000 to RMB400,000 price segment. All models come standard with an all-weather LiDAR to deliver industry-leading automatic emergency braking and automatic emergency steering active safety capabilities.
Confident Investing Starts Here:
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Miami Herald
6 hours ago
- Miami Herald
Tesla's Top Rival BYD Ignites EV Pricing War in China
BYD has reignited China's electric vehicle (EV) price war after lowering the price of 22 all-electric and plug-in hybrid vehicles by up to 34% through the end of June. Subsequently, shares of many Chinese EV makers, including BYD, tumbled. The Seal hybrid sedan saw the most significant price cut in BYD's lineup at 34%, lowering its starting cost to $15,000 or 102,800 yuan. However, BYD's price changes don't impact its luxury inventory, which includes the Denza FangChengBao and Yangwang lines. China's IM Motors, Leapmotor, and Geely's Galaxy have also announced price cuts in response to BYD's move. Other key players, like XPeng, Nio, and Li Auto, haven't yet slashed any price tags. European automakers like Volkswagen, BMW, and Mercedes-Benz will likely see further EV sales declines in China after BYD's bold move, given their reluctance to enter the country's new energy vehicle (NEV) price war. Tesla China registrations have also lagged in Q2. BYD has been considered a leader in China's EV price war with its in-house battery production and ability to get volume discounts from suppliers. The automaker is one of China's three profitable EV makers among the country's 50 or so electric car manufacturers. According to Investor's Business Daily, BYD introduced its latest price cuts in response to rising dealer inventories, causing some to wonder whether China's NEV push is losing steam. Chinese officials have also been investigating the possibility of zero-mileage car sales, where automakers pad their delivery numbers by reporting vehicles as sold that are being distributed to finance companies and used auto dealers, Clean Technica reports. In other words, Chinese automakers might be recording zero-mileage cars as sold when end users haven't purchased them. A slowdown in NEV sales would be a significant concern among Chinese officials regarding the country's economic goals and environmental sustainability. New price cuts from BYD also stem from the automaker's desire to reach 5.5 million sales this year, representing a 1.5 million increase from 2024. BYD's U.S. stocks declined 9.75% on Tuesday after the company's pricing announcement, while XPeng, Nio, and Li Auto's U.S. shares fell 3.8%, 4.1%, and 2.6%, respectively, according to Investor's Business Daily. Close to half of all China's new car sales are all-electric and PHEV, Electrek reports. By comparison, less than 10% of U.S. new vehicle sales are NEVs. Victor Sun, senior equity analyst at Morningstar, said he expects BYD to: "Offset the impact [of its discounts] via larger sales scale and [its] battery cost staying low," according to CNBC. Market reactions to BYD's discounts reflect how investors are nervous about an escalating EV price war in China and increased scrutiny from the country's regulators regarding sales numbers. In April, China's EV discounts reached a record high of 16.8%, and it appears this figure will climb higher in May. BYD, Seres, and Li Auto are the only three Chinese EV makers currently profitable, and an intensifying price war is setting the stage for an industry shakeout where smaller competitors will likely go under or get bought out by competitors. Copyright 2025 The Arena Group, Inc. All Rights Reserved.
Yahoo
7 hours ago
- Yahoo
Construction in Crisis: Inter/Arch Jobs Raises Awareness for Men's Mental Health Month
Leading job board addresses suicide rates and mental health stigma among male workers in the built environment. SHERIDAN, Wyo., June 3, 2025 /PRNewswire/ -- June is Men's Mental Health Month, and Inter/Arch Jobs, one of the world's leading job boards and staffing platforms for architecture, engineering, and construction professionals, is spotlighting the urgent mental health crisis impacting male construction workers. While construction is one of the largest industries worldwide, it also carries a tragic distinction: it has one of the highest suicide rates of any profession. According to the CDC, male construction workers are nearly four times more likely to die by suicide than the general population. Data from the Construction Industry Alliance for Suicide Prevention shows that 1 in 5 construction workers struggle with mental health issues, yet stigma and fear of job loss often keep them silent. "Construction workers—many of whom are men—are trained to be tough and resilient. But that cultural expectation has created a silence that's costing lives," says Richard Eib, Managing Director of Inter/Arch Jobs. "This Men's Mental Health Month, we're breaking that silence." Supporting Men Where They Work Inter/Arch Jobs is taking a proactive stance to support the mental health of men in the built environment by: Curating job listings with a focus on work-life balance, benefits, and psychological safety. Partnering with progressive employers who offer Employee Assistance Programs (EAPs), mental health days, and open-door mental health policies. Launching a resource hub this month with articles, guides, and interviews focused on managing stress, burnout, and job-related trauma. Promoting anonymous candidate matching, so professionals can explore better opportunities without the fear of retaliation or exposure. "We believe finding the right job isn't just about salary or title—it's about fit, culture, and well-being," Eib adds. "By connecting candidates to employers who genuinely value mental health, we're helping build careers that support both personal well-being and professional growth." Breaking the Stigma in the Trades Construction, engineering, and design have long been male-dominated fields where vulnerability is often seen as weakness. This stigma has contributed to chronic stress, substance use, and isolation. But Inter/Arch Jobs is changing the narrative. Through its job board and talent network, the company not only places candidates into meaningful roles globally, but is committed to leading industry-wide conversations around mental wellness in AEC (Architecture, Engineering, and Construction). Join the Movement As part of this month's campaign, Inter/Arch Jobs is launching a social media initiative under the hashtag #BuiltForWellbeing, inviting firms and individuals to share how they support men's mental health in the workplace. Visit to access resources that support this mission. For media inquiries, please contact: Richard EibManaging Directorpr@ 213-1335 About Inter/Arch Jobs Inter/Arch Jobs is a global career platform dedicated to connecting professionals across architecture, interior design, and engineering disciplines with leading employers, resources, and community networks in the built environment. View original content to download multimedia: SOURCE Inter/Arch Jobs LLC Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
8 hours ago
- Yahoo
Gabapentin Market Size to Hit USD 3.55 Billion by 2032, Driven by Rising Cases of Epilepsy, Neuropathic Pain, and Off-Label Use
U.S. Gabapentin Market Growth is Fueled by High Chronic Pain Prevalence and Broad Generic Adoption. Austin, June 03, 2025 (GLOBE NEWSWIRE) -- According to SNS Insider, the global Gabapentin market was USD 2.33 billion in 2023, is projected to reach USD 3.55 billion by 2032, expanding at a compound annual growth rate (CAGR) of 4.75% during the forecast period. The growth is primarily driven by increasing cases of epilepsy, post-herpetic neuralgia, and neuropathic pain—especially within aging populations—alongside expanded off-label use for conditions such as fibromyalgia, anxiety, and a Sample Report of Gabapentin Market@ The U.S. market, valued at USD 0.62 billion in 2023, is expected to grow to USD 0.94 billion by 2032 at a CAGR of 4.78%. Factors contributing to this growth include the high prevalence of chronic pain, widespread adoption of generic alternatives, and increasing prescription rates among mental health professionals. The CDC reports that over 20% of U.S. adults experience chronic pain, underlining the need for non-opioid treatment options like gabapentin. Additionally, rising epilepsy rates reported by the National Institute of Neurological Disorders and Stroke further reinforce gabapentin's clinical relevance. Segment Analysis By Dosage Form: Capsule Dominate Market With a 55.27% market share in 2023, the capsule segment dominated the global gabapentin market because of its convenience, broad prescription base, and preferred dose form in long-term neurological treatment. Patients with persistent neurological diseases might find capsules appealing since they have a higher shelf life and are easy to swallow. Their consistency during travel and capacity to hide the flavor of active components further improve patient adherence. Healthcare professionals choosing capsules over other forms because of their consistent bioavailability helps the segment even more. By Type: The Generic segment dominated the market With and held 89.56% share of the Gabapentin Market in 2023, the generic segment, because of its cost-effectiveness and same therapeutic benefits as branded equivalents like Neurontin, the generic form of gabapentin is being used. Most patents on branded gabapentin formulations have expired, so market rivalry among generic medicine producers has been more intense, resulting in lower pricing and better accessibility. By Application: Epilepsy Segment Maintains Highest Share With a 50.26% market share in 2023, the epilepsy segment dominated the gabapentin market in terms of application. Regulatory agencies such as the European Medicines Agency and the U.S. FDA have approved gabapentin's effectiveness in controlling partial seizures after adequately recorded data. Often recommended as an additional therapy for patients not responding to monotherapy, the demand for efficient antiepileptic medications such as gabapentin is still driven by the rising worldwide frequency of epilepsy, estimated by the WHO to impact over 50 million individuals. By Distribution Channel: Hospital pharmacies dominated the market. Hospital pharmacies accounted for 48.59% of the total gabapentin market revenue in 2023. Particularly for chronic neurological and pain-related disorders, the great volume of gabapentin prescriptions written during inpatient and outpatient visits accounts for this supremacy. For newly diagnosed epilepsy or neuralgia sufferers, hospitals also provide the primary point of care, thereby depending more on institutional pharmacy systems. Hospitals are looking to gabapentin as a preferable non-opioid alternative for post-surgical and neuropathic pain, as tighter control of opioid prescriptions calls for. Need Any Customization Research on Gabapentin Market, Enquire Now@ Regional Analysis North America is leading the Gabapentin Market in 2023, with 36.62% of the global market share. High diagnosis rates, modern healthcare infrastructure, and general acceptance of generic drugs help to explain this supremacy. Major pharmaceutical companies and good reimbursement policies help to drive large prescription volumes between general and specialty care physicians even more. Demand in the area also stems from the growing frequency of disorders, including spinal injuries and diabetic neuropathy. Asia Pacific is likely to see a notable increase throughout the forecast period, driven by a rise in epilepsy and diabetes-related neuropathy, expanding healthcare coverage, and government initiatives aiming at improving access to necessary pharmaceuticals. Major Players Analysis Listed in this Report are: Zydus Pharmaceuticals, Inc. Teva Pharmaceutical Industries Ltd Sun Pharmaceutical Industries Ltd. Pfizer Inc. GLENMARK PHARMACEUTICALS LTD. Cipla B.P. Pharma Aurobindo Pharma Assertio Holdings, Inc. Ascend Laboratories LLC Arbor Pharmaceuticals, LLC (Azurity Pharmaceuticals, Inc.) Apotex Inc. Amneal Pharmaceuticals LLC. Recent advancements Teva Pharmaceuticals debuted an extended-release form of gabapentin in the United States for once-daily dosing in November 2023, therefore enhancing compliance among those suffering from chronic pain. Further bolstering the generic supply chain was U.S. FDA clearance of Dr. Reddy's Laboratories' generic gabapentin 300 mg and 600 mg capsules in January 2024. Pfizer Inc. revealed in March 2024 a joint research project including academic institutions to investigate gabapentin's potential in controlling chemotherapy-induced neuropathy. Buy a Single-User PDF of Gabapentin Market Analysis & Outlook Report 2024-2032@ About Us: SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world. CONTACT: Contact Us: Jagney Dave - Vice President of Client Engagement Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK)Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
